Fumaric Acid

Fumaric Acid

SCHEMBL2238207

Clc1ccc(OC2CC3CCC(C2)N3Cc2ccccn2)nc1.O=C(O)/C=C/C(=O)O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KCNH2 known ✓ Q12809 12/20 0.55
OPRK1 P41145 9/20 0.55
OPRM1 P35372 4/20 0.52
OPRD1 P41143 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL2238216 1.00 KCNH2 (0.55) KCNH2OPRK1OPRM1OPRD1L3MBTL1
SCHEMBL2235487 0.91 KCNH2 (0.53) KCNH2OPRK1OPRM1
Fumaric Acid SCHEMBL2236891 0.85 KCNH2 (0.57) KCNH2OPRK1OPRM1OPRD1
Fumaric Acid SCHEMBL2236898 0.85 KCNH2 (0.57) KCNH2OPRK1OPRM1OPRD1
Fumaric Acid SCHEMBL2234437 0.84 KCNH2 (0.59) KCNH2OPRK1OPRM1OPRD1
Fumaric Acid SCHEMBL2234450 0.84 KCNH2 (0.59) KCNH2OPRK1OPRM1OPRD1
Fumaric Acid SCHEMBL2236126 0.81 KCNH2 (0.54) KCNH2OPRK1OPRM1OPRD1
Fumaric Acid SCHEMBL2236115 0.81 KCNH2 (0.54) KCNH2OPRK1OPRM1OPRD1
Fumaric Acid SCHEMBL2236903 0.81 KCNH2 (0.62) KCNH2OPRK1OPRM1OPRD1
Fumaric Acid SCHEMBL2236909 0.81 KCNH2 (0.62) KCNH2OPRK1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989470-B2 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-08-02 US disclosed
US-20100190821-A1 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2010-07-29 US disclosed
US-7713990-B2 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-05-11 US disclosed
US-20080004252-A1 3,8-Substituted 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monomine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2008-01-03 US disclosed
EP-1838705-A2 3,8-SUBSTITUTED 8-AZA-BICYCLO [3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-10-03 EP disclosed
WO-2006075004-A2 3, 8 - SUBSTITUTED 8-AZA-BICYCLO[3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190821-A1 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC18A3, SLC6A2 KCNH2 1080/4885OPRK1 185/4885OPRM1 87/4885
US-20080004252-A1 3,8-Substituted 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monomine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC18A3, SLC6A2 KCNH2 1080/4885OPRK1 185/4885OPRM1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.